secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-133770
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics Q1: THRIVE TED trial enrollment completed (113 pts); topline data Sept 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments of $613.2M as of March 31, 2024, sufficient into H2 2026.
- Net loss of $48.5M for Q1 2024, compared to $68.2M in Q1 2023.
- THRIVE global phase 3 trial in active TED enrolled 113 patients (exceeded target of 90); topline data expected September 2024.
- Positive FDA Type C meeting for VRDN-003 subcutaneous candidate; pivotal program on track to start mid-2024.
- VRDN-006 FcRn inhibitor IND submission on track for year-end 2024; VRDN-008 NHP data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/d823086d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer